semaglutide fda ruling FDA's Removal of and the Evolving Tirzepatide Decisions: What Compounders Need to Know Messaged provider re: GLP-1 discontinuation

In WHOs VigiBase, which documented over 35 million cases, these drugs accounted for 118,639 instances (0.34%)

Saunders AM, Strittmatter WJ, Schmechel D, et al

doi: 10.1016/j.jtemb.2011.11.003

Should I stop taking inositol if I start a weight loss medication

Possible concerns with peptide use may include: Injection site irritation Headache Dizziness Nausea Fatigue Unexpected sleep changes Allergic or immune reactions Contamination risk from poor sourcing Incorrect dosing Medication interactions Unknown long-term safety risks Safety concerns can also depend on the route of administration, dose, product quality, and patient health history

Limitations of Use: IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR-deficiency with POMC, PCSK1, or LEPRvariants classified as benign or likely benign